In 2022, the global Rare Disease Clinical Trials Market is expected to be worth USD 11548.5 million.
The Rare Disease Clinical Trials Market is estimated to increase at a CAGR of 9.90% between 2023 and 2030, reaching USD 24575.7 Million in 2030.
Pharmaceutical and biopharmaceutical firms will have the biggest revenue share of 58.5% in 2022
The two most important segments in the Rare Disease Clinical studies Market are interventional studies and observational trials.
During the projected period, Phase III is expected to increase at the fastest CAGR
North America had the highest revenue share of 49.3% in 2022
The top players include Takeda Pharmaceutical Company; F. Hoffmann-La Roche Ltd.; Pfizer, Inc.